Wed, 07 Dec 2022

NEW YORK, NY / ACCESSWIRE / September 29, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

KRBP Shareholders Click Here: https://www.zlk.com/pslra-1/kiromic-lawsuit-submission-form?prid=32255&wire=1
TUYA Shareholders Click Here: https://www.zlk.com/pslra-1/tuya-lawsuit-loss-submission-form?prid=32255&wire=1
CODX Shareholders Click Here: https://www.zlk.com/pslra-1/co-dx-lawsuit-loss-submission-form?prid=32255&wire=1

* ADDITIONAL INFORMATION BELOW *

Levi & Korsinsky, LLP, Thursday, September 29, 2022, Press release picture

Kiromic BioPharma, Inc. (NASDAQ:KRBP)

This lawsuit is on behalf of a class consisting of persons and entities that purchased or otherwise acquired: (a) Kiromic common stock issued in connection with the Company's public offering that closed on July 2, 2021 and/or (b) Kiromic common stock between June 25, 2021 and August 13, 2021, both dates inclusive.
Lead Plaintiff Deadline : October 4, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/kiromic-lawsuit-submission-form?prid=32255&wire=1

The complaint alleges that the registration statement and prospectus issued in connection with the Company's public offering that closed on July 2, 2021 (the 'Offering Documents') failed to disclose that the Food and Drug Administration ('FDA') had, prior to the filing of these documents, imposed a clinical hold on the Company's Investigational New Drug ('IND') applications for its two new drug candidates. Given that the offering closed on July 2, 2021, more than thirty (30) days after the Company submitted the IND applications for its two immunotherapy product candidates, investors were assured that no clinical hold had been issued and clinical trials would commence.

Tuya Inc. (NYSE:TUYA)

This lawsuit is on behalf of all persons or entities who purchased Tuya American Depositary Shares in or traceable to the Company's March 2021 initial public offering.
Lead Plaintiff Deadline : October 11, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/tuya-lawsuit-loss-submission-form?prid=32255&wire=1

According to the filed complaint, (a) a material portion of Tuya's China-based customers were engaged in the widespread and systematic manipulation of reviews and product offerings in violation of Amazon.com's terms of use; (b) prior to the initial public offering, a consumer investigation and data breach had exposed an illicit fake review scheme being perpetrated by many of Tuya's clients, among others, which included, inter alia, the exposure of 13 million records of organized fake review scams linked to over 200,000 Amazon account profiles; (c) as a result of (a) and (b) above, there was a substantial risk that a material portion of Tuya's significant customers would be barred from using Amazon.com's platform, negatively impacting Tuya's business, revenue, earnings, and prospects; and (d) as a result of (a)-(c) above, the registration statement's representations regarding Tuya's historical financial and operational metrics and purported market opportunities and expected growth did not accurately reflect the actual business, operations, financial results, and trajectory of the Company at the time of the initial public offering, and such statements were materially false and misleading and lacked a reasonable factual basis.

Co-Diagnostics, Inc. (NASDAQ:CODX)

This lawsuit is on behalf of a class of all persons and entities who purchased the publicly traded securities of Co-Dx during the period of May 12, 2022 through the close of the market on August 11, 2022 (4:00 p.m. ET).
Lead Plaintiff Deadline : October 17, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/co-dx-lawsuit-loss-submission-form?prid=32255&wire=1

According to the filed complaint, (i) demand for the Company's Logix Smart™ COVID-19 test had plummeted throughout the quarter ended June 30, 2022, and (ii) as a result, defendants' positive statements about the demand for its Logix Smart™ COVID-19 test lacked a reasonable basis.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP



View source version on accesswire.com:
https://www.accesswire.com/718243/CLASS-ACTION-UPDATE-for-KRBP-TUYA-and-CODX-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders

More Philadelphia News

Access More

Sign up for Philadelphia News

a daily newsletter full of things to discuss over drinks.and the great thing is that it's on the house!